• Prolonged adjuvant anastrozole confers no DFS benefit in postmenopausal breast cancer

    1 month ago - By Healio

    A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, according to randomized phase 3 study results.
    The findings - published in The New England Journal of Medicine - showed no statistically significant difference in DFS between women who received 5 years vs. 2 years of extended hormone therapy.
    In addition, women who received extended therapy demonstrated a higher risk for adverse effects and bone fracture.
    “In this trial, we did not
    Read more ...